Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
Злокачественное новообразование костей и суставных хрящей конечностей
Simin Kiany, Nancy Gordon
Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and EffectMethods Mol Biol. 2016;1441:285-95.
Sergei R Guma, Dean A Lee, Ling Yu, Nancy Gordon, Dennis Hughes, John Stewart, Wei Lien Wang, Eugenie S Kleinerman
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasisPediatr Blood Cancer. 2014 Apr;61(4):618-26.
Sergei R Guma, Dean A Lee, Yu Ling, Nancy Gordon, Eugenie S Kleinerman
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasisPediatr Blood Cancer. 2014 Aug;61(8):1362-8.
Исмаилзаде Р.С., Белевцев М.В., Потапнев М.П. и др. 
PDF
Медицинская иммунология. — 2006. — №4. — С. 561-566.
Новиков В.И., Власов А.А., Карандашов В.И., Сидорович И.Г.
Препараты, методы и схемы иммунотерапии опухолей.
Справочник. М.: ОАО «Издательство «Медицина». 2006. 152 с.
Златник Е.Ю., Нестерова Ю.А., Закора Г.И. и др. PDF
Применение Ронколейкина в комплексном лечении злокачественных новообразований у детей.
Детские инфекции. 2005. Том 4. № 2. С. 56-59.
Исмаилзаде Р.С., Буглова С.Е., Потапнёв М.П. и др.
Термохимиотерапия при рефрактерных и далеко зашедших злокачественных опухолях у детей.
Вопросы онкологии. 2002. Т. 48. № 3. С. 351-355.
Алейникова О.В., Исмаилзаде Р.С., Конопля Н.Е., Потапнев М.П.
Ронколейкин® в лечении злокачественных опухолей у детей.
Матер. науч.-практ. конф. “Современная фармакотерапия: цитокины”. Минск, БелГИУВ, 2000. С.40-42.
Киселёва И.В., Протасова С.Ф., Жунко В.В., Щеканова С.М.
Цитокины в лечении рака.
Русский журнал ВИЧ/СПИД и родственные проблемы. 1999. Т. 3. № 1. С. 48.
Mertens WC, Banerjee D, al-Mutter N et al.
High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.Cancer Immunol Immunother. 1995 Nov;41(5):271-9. doi: 10.1007/BF01517214. PMID: 8536272.
Zambello R, Trentin L, Cerutti A et al.
Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.Cancer. 1994 Nov 1;74(9):2562-9. doi: 10.1002/1097-0142(19941101)74:9<2562::aid-cncr2820740926>3.0.co;2-1. PMID: 7522954.
Caligiuri MA, Murray C, Robertson MJ et al.
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.J Clin Invest. 1993 Jan;91(1):123-32. doi: 10.1172/JCI116161. PMID: 7678599; PMCID: PMC330005.
Gratama JW, Bruin RJ, Lamers CH et al.
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x. PMID: 8485906; PMCID: PMC1554808.
Eberlein TJ, Schoof DD.
The role of interleukin-2 in cancer immunotherapy.Compr Ther. 1991 Jan;17(1):49-56. PMID: 2001612.
Farace F, Mathiot C, Brandely M et al.
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.Clin Exp Immunol. 1990 Nov;82(2):194-9. doi: 10.1111/j.1365-2249.1990.tb05426.x. PMID: 2122928; PMCID: PMC1535125.
Parkinson DR.
Lessons from the clinical trials of interleukin-2.Nat Immun Cell Growth Regul. 1990;9(4):242-52. PMID: 2215513.
Kolitz JE, Wong GY, Welte K et al.
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.J Biol Response Mod. 1988 Oct;7(5):457-72. PMID: 3263471.
Ettinghausen SE, Rosenberg SA.
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.Cancer Res. 1986 Jun;46(6):2784-92. PMID: 3486038.
Harel-Bellan A, Bertoglio J, Quillet A et al.
Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.J Immunol. 1986 Apr 1;136(7):2463-9. PMID: 3005412.
Thurman GB, Maluish AE, Rossio JL et al.
Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations.J Biol Response Mod. 1986 Feb;5(1):85-107. PMID: 3514800.
Ortaldo JR, Mason AT, Gerard JP et al.
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.J Immunol. 1984 Aug;133(2):779-83. PMID: 6203980.
Vose BM, Bonnard GD.
Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells.J Immunol. 1983 Feb;130(2):687-93. PMID: 6600251.